Thromb Haemost 2008; 99(03): 461-462
DOI: 10.1160/TH08-02-0072
Editorial Focus
Schattauer GmbH

Perplexity of monocyte responses to C-reactive protein (CRP)

János G. Filep
1   Research Center, Maisonneuve-Rosemont Hospital, University of Montreal, Montral, Quebec, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 06. Februar 2008

Accepted after major revision: 06. Februar 2008

Publikationsdatum:
07. Dezember 2017 (online)

 

 
  • 1 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
  • 2 Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
  • 3 Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-519.
  • 4 Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable plaque. JAmColl Cardiol 2006; 47: C19-C31.
  • 5 Danesh J, Wheeeler JG, Hirschfeld G. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
  • 6 Scirica BM, Morrow DA, Verma S. et al. Is C-reactive protein an innocent bystander or proatherogenic culprit?. Circulation 2006; 113: 2128-2151.
  • 7 Paul A, Ko KW, Li L. et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-655.
  • 8 Schwedler SB, Amann K, Wernicke K. et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: 1016-1023.
  • 9 Hirschfield GM, Gallimore JR, Kahan MC. et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005; 102: 8309-8314.
  • 10 Kovacs A, Tornwall P, Nilsson R. et al. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007; 104: 13768-13773.
  • 11 Ballou CP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes. Cytokine 1992; 4: 361-368.
  • 12 Xie L, Chang L, Guan Y. et al. CRP augments IL-8 secretion in human peripheral blood monocytes. J Cardiovasc Pharmacol 2005; 46: 690-696.
  • 13 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
  • 14 Devaraj S, Davis B, Simon SI. et al. CRP promotes monocyte-endothelial cell adhesion via Fcγ receptors in human aortic endothelial cells under static and shear flowconditions. AmJ Physiol Heart Circ Physiol 2006; 291: H1170-H1176.
  • 15 Hanriot D, Bello G, Ropars A. et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes. Thromb Haemost 2008; 99: 558-569.
  • 16 Szalai AJ, Nataf S, Hu XZ. et al. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002; 168: 5792-5797.
  • 17 Scott J. The liver X receptor and atherosclerosis. N Engl J Med 2007; 357: 2195-2197.
  • 18 Khreiss T, Jozsef L, Potempa LA. et al. Loss of pentameric symmetry in C-reactive protein induces interleukin- 8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 2005; 97: 690-697.
  • 19 Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-1932.
  • 20 Sun H, Koike T, Ichikawa T. et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 2005; 167: 1139-1148.